Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.468
Peer-review started: December 20, 2023
First decision: February 2, 2024
Revised: February 16, 2024
Accepted: March 6, 2024
Article in press: March 6, 2024
Published online: April 24, 2024
Processing time: 124 Days and 4.3 Hours
In this editorial we comment on the article by Wei et al, published in the recent issue of the World Journal of Clinical Oncology. The authors investigated the role of Transmembrane 9 superfamily member 1 (TM9SF1) protein in bladder cancer (BC) carcinogenesis. Lentiviral vectors were used to achieve silencing or overexpression of TM9SF1 gene in three BC cell lines. These cell lines were then subject to cell counting kit 8, wound-healing assay, transwell assay, and flow cytometry. Proliferation, migration, and invasion of BC cells were increased in cell lines subjected to TM9SF1 overexpression. TM9SF1 silencing inhibited proliferation, migration and invasion of BC cells. The authors conclude that TM9SF1 may be an oncogene in bladder cancer pathogenesis.
Core Tip: The scratch wound healing assay and transwell assay showed significantly improved cellular migration in the Transmembrane 9 superfamily member 1 (TM9SF1) overexpression group. TM9SF1 silencing inhibited proliferation, migration and invasion of bladder cancer (BC) cells. TM9SF1 can be used as a therapeutic molecular target. The importance of TM9SF1 as an oncogene and its use as a therapeutic target would ultimately depend on the prevalence of the mutation in BC tissues and replication of in vitro activity in tumour tissue.